Quantitation of HCV RNA with the microwell plate and COBAS Amplicor HCV Monitor assays

被引:1
作者
Arens, M [1 ]
机构
[1] Washington Univ, Sch Med, St Louis Childrens Hosp, Dept Pediat, St Louis, MO 63110 USA
关键词
hepatitis C virus; HCV RNA; COBAS Amplicor HCV Monitor;
D O I
10.1016/S1386-6532(02)00176-2
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: We performed the Roche Amplicor Monitor hepatitis C virus (HCV) v2.0 microwell plate (MWP) assay for 2 years prior to bringing a COBAS instrument into the lab. Before reporting any results from the automated COBAS Amplicor Monitor HCV v2.0, we compared quantitative data with results on the same specimens from the manual Amplicor Monitor HCV. Objective: To determine if the COBAS Amplicor Monitor assay yielded quantitative results that were comparable with those given by the manual Amplicor Monitor HCV. Study design: We tested 145 specimens with both assays. Specimens were chosen on the basis of having fallen within the linear range of the first assay. Results: The log(10) mean (+/-standard deviation) for all 145 specimens was 5.976 (+/-0.597) for the COBAS and 6.142 (+/-0.597) for the MWP assay. When plotted as 145 pairs of numbers (log MWP result vs. log COBAS result), the linear regression line was displaced slightly downward from the line of equivalence by 0.1 log at the lower end and by 0.2 log at the upper end indicating the COBAS result was somewhat lower than the MWP result across the full range of the assay. The mean of the difference of the manual method and the COBAS for all 145 specimens was 0.166 log(10). A subset of 45 specimens for which we had HCV genotype data was analyzed separately. This set of specimens (of which 33 were genotype 1) also showed excellent concordance between the automated and manual methods. The two trendlines. one for genotype 1 and the other for genotypes 2, 3 and 4, were superimposable, and thus the quantitative results were apparently not influenced by the genotypes, although the numbers were small (six HCV genotype 2, five HCV genotype 3 and one HCV genotype 4). Conclusions: We conclude that the automated Roche COBAS Amplicor Monitor v2.0 yields results that are comparable with the manual Amplicor Monitor assay for HCV genotype I and possibly also for genotypes 2, 3 and 4. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:235 / 241
页数:7
相关论文
共 9 条
[1]   Evaluation of hepatitis C virus RNA RT/PCR qualitative and quantitative second generation assays [J].
Castro, FJ ;
Sauleda, S ;
Esteban, JI ;
Viladomiu, L ;
Martell, M ;
Dragon, E ;
Esteban, R ;
Guardia, J .
JOURNAL OF VIROLOGICAL METHODS, 2001, 91 (01) :51-58
[2]   Is severe liver disease a common outcome for people with chronic hepatitis C? [J].
Dore, GJ ;
Freeman, AJ ;
Law, M ;
Kaldor, JM .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 (04) :423-430
[3]   Performance characteristics of the COBAS AMPLICOR Hepatitis C Virus MONITOR Test, version 2.0 [J].
Erali, M ;
Ashwood, ER ;
Hillyard, DR .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 114 (02) :180-187
[4]  
Gerken G, 2000, J CLIN MICROBIOL, V38, P2210
[5]   Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: Calibration to international units, enhanced genotype reactivity, and performance characteristics [J].
Lee, SC ;
Antony, A ;
Lee, N ;
Leibow, J ;
Yang, JQ ;
Soviero, S ;
Gutekunst, K ;
Rosenstraus, M .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (11) :4171-4179
[6]   Assessment of viral loads in patients with chronic hepatitis C with AMPLICOR HCV MONITOR version 1.0, COBAS HCV MONITOR version 2.0, and QUANTIPLEX HCV RNA version 2.0 assays [J].
Martinot-Peignoux, M ;
Le Breton, V ;
Fritsch, S ;
Le Guludec, G ;
Labouret, N ;
Keller, F ;
Marcellin, P .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (07) :2722-2725
[7]   Hepatitis C advances in antiviral therapy: What is accepted treatment now? [J].
McHutchison, JG .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 (04) :431-441
[8]   Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C [J].
McHutchison, JG ;
Gordon, SC ;
Schiff, ER ;
Shiffman, ML ;
Lee, WM ;
Rustgi, VK ;
Goodman, ZD ;
Ling, MH ;
Cort, S ;
Albrecht, JK .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1485-1492
[9]   Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C [J].
Reichard, O ;
Norkrans, G ;
Frydén, A ;
Braconier, JH ;
Sönnerborg, A ;
Weiland, O .
LANCET, 1998, 351 (9096) :83-87